NO943654L - Decorin fragments and methods for inhibiting cell regulatory factors - Google Patents

Decorin fragments and methods for inhibiting cell regulatory factors

Info

Publication number
NO943654L
NO943654L NO943654A NO943654A NO943654L NO 943654 L NO943654 L NO 943654L NO 943654 A NO943654 A NO 943654A NO 943654 A NO943654 A NO 943654A NO 943654 L NO943654 L NO 943654L
Authority
NO
Norway
Prior art keywords
cell regulatory
methods
protein
regulatory factors
cell
Prior art date
Application number
NO943654A
Other languages
Norwegian (no)
Other versions
NO943654D0 (en
Inventor
Erkki I Ruoslahti
Michael D Pierschbacher
Jose Cardenas
William Scot Craig
Daniel G Mullen
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Publication of NO943654D0 publication Critical patent/NO943654D0/en
Publication of NO943654L publication Critical patent/NO943654L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Fremgangsmåte for inhibering av en aktivitet av en celleregulerings- faktor som omfatter å bringe celle- reguleringsfaktoren i kontakt med et renset polypeptid, hvor polypeptidet omfatter et cellereguleringsfaktorbin- dende domene fra et protein. Proteinet karakteriseres ved en leucinrik repeti- sjon på tilnærmet 24 aminosyrer. I en spesifikk utførelse gjelder foreligg- ende oppfinnelse evnen til decorin, et protein på 40.000 dalton som vanligvis bærer en glykosaminoglykankjede, og mer spesifikt aktive deoorinfragmenter eller disses funksjonelle ekvivalenter, til å binde TGFp. Oppfinnelsen tilveie- bringer også en ny cellereguleringsfak- tor kalt MRF. Videre tilveiebringes fremgangsmåter for identifisering, på- visning og rensing av celleregulerings- faktorer og proteiner som binder og påvirker aktiviteten av cellereguler- ings faktorer.A method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises a cell regulatory factor binding domain of a protein. The protein is characterized by a leucine-rich repetition of approximately 24 amino acids. In a specific embodiment, the present invention relates to the ability of decorin, a 40,000 dalton protein that usually carries a glycosaminoglycan chain, and more specifically active deoorin fragments or their functional equivalents, to bind TGFβ. The invention also provides a new cell regulation factor called MRF. Furthermore, methods are provided for identifying, detecting and purifying cell regulatory factors and proteins that bind and affect the activity of cell regulatory factors.

NO943654A 1992-04-03 1994-09-30 Decorin fragments and methods for inhibiting cell regulatory factors NO943654L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86565292A 1992-04-03 1992-04-03
PCT/US1993/003171 WO1993020202A1 (en) 1992-04-03 1993-04-02 Decorin fragments and methods of inhibiting cell regulatory factors

Publications (2)

Publication Number Publication Date
NO943654D0 NO943654D0 (en) 1994-09-30
NO943654L true NO943654L (en) 1994-12-05

Family

ID=25345963

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943654A NO943654L (en) 1992-04-03 1994-09-30 Decorin fragments and methods for inhibiting cell regulatory factors

Country Status (7)

Country Link
EP (1) EP0636175A1 (en)
JP (1) JPH07508403A (en)
AU (1) AU679178B2 (en)
CA (1) CA2132859A1 (en)
FI (1) FI944575A (en)
NO (1) NO943654L (en)
WO (1) WO1993020202A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157388C (en) * 1993-03-01 1998-12-15 Daniel P. Witt Analogs for specific oligosaccharide-protein interactions and uses thereof
US5567807A (en) * 1994-07-08 1996-10-22 La Jolla Cancer Research Foundation Processes for the purification of human recombinant decorin and the detection of guanidinium ions
JP2008503205A (en) * 2004-05-31 2008-02-07 ナショナル ユニヴァーシティ オブ シンガポール Peptide derived from decorin leucine rich repeat and use thereof
DK1806359T3 (en) * 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumor-associated peptides promiscuously bound to human leukocyte antigen (HLA) class II molecules
ES2283212B1 (en) * 2006-03-31 2008-08-16 Lipotec S.A. USEFUL SYNTHETIC PEPTIDES IN THE TREATMENT OF SKIN AND ITS USE IN COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS.
HU0700024D0 (en) * 2007-01-11 2007-03-28 Mta Szegedi Biolog Koezpont Use of enhancers in biglycan activuty in the preparation of pharmaceutical compositions having utility in cardiac diseases
EP2538221A3 (en) * 2007-11-05 2013-04-24 Nordic Bioscience A/S Biochemical markers for CVD risk assessment
US20120238727A1 (en) * 2011-03-14 2012-09-20 Catalent Pharma Solutions Llc Decorin compositions and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors

Also Published As

Publication number Publication date
AU679178B2 (en) 1997-06-26
FI944575A0 (en) 1994-09-30
JPH07508403A (en) 1995-09-21
WO1993020202A1 (en) 1993-10-14
NO943654D0 (en) 1994-09-30
CA2132859A1 (en) 1993-10-14
AU4025793A (en) 1993-11-08
FI944575A (en) 1994-11-29
EP0636175A1 (en) 1995-02-01

Similar Documents

Publication Publication Date Title
Burke et al. Synthesis of connective tissue macromolecules by smooth muscle
NO941821D0 (en) Inhibitors of cell regulation factors as well as methods of prevention or reduction of scarring
NZ501767A (en) Cyclic integrin binding peptide with the amino acid sequence RKK
Jander et al. A collagen-like glycoprotein of the extracellular matrix is the undegraded form of type VI collagen
ATE224713T1 (en) USE OF PYRIDYL-ALKANEOUS, PYRIDIYL ALKANEOUS AND/OR PYRIDYL ACIDS AMIDES FOR THE TREATMENT OF TUMORS OR FOR IMMUNOSUPRESSION
KR970702917A (en) Soluble polypeptide fragment of LAG-3 and production method, therapeutic composition, anti-idiotype antibody
IL101728A0 (en) Human notch and delta,binding domains in toporhythmic proteins,and methods based thereon
NO943654L (en) Decorin fragments and methods for inhibiting cell regulatory factors
ATE226634T1 (en) FIBRONECTIN BINDING PROTEIN
YU218690A (en) PROCEDURE FOR PREPARATION OF PROTEIN COMPLEXES IN WHICH FACTOR VIII ACTS: C
DK0572688T3 (en) Peptides, with organ-protective activity, method for their preparation and their use in therapy
DE69435020D1 (en) Protein-tyrosin-phosphatase ptp-s31
NO962084L (en) DNA sequence encoding a BMP receptor
HK1043372A1 (en) Hypoxia-inducible factor 1a hif-1a variants and methods for identifying hif-1a modulators
EP0319315A3 (en) The von willebrand factor binding domain of factor viii
Madsen et al. Analysis of collagen types synthesized by rabbit ear cartilage chondrocytes in vivo and in vitro
ATE356145T1 (en) POLYPEPTIDES FOR REGENERATING THE NERVOUS SYSTEM
Lester et al. Human alpha-fetoprotein: immunosuppressive activity and microheterogeneity
Ayad et al. Type VI collagen and glycoprotein MFPI are distinct components of the extracellular matrix.
WO1997014966B1 (en) Method of activating a novel ligand regulatory pathway
DE69229356T2 (en) NEW IMPROVEMENTS IN RADIO MARKING PROTEINS
Schreier et al. The tissue form of chicken type VI collagen
DE68904578D1 (en) ENZYME FOR ALPHA AMIDATION OF C-TERMINI AND METHOD FOR THE PRODUCTION THEREOF.
Narayanan et al. Studies on the action of lysyl oxidase on soluble elastin
Leushner et al. The effect of ascorbate on the synthesis of minor (non-interstitial) collagens by cultured bovine aortic smooth muscle cells